Cardiovascular and nonalcoholic fatty liver disease: Sharing common ground through SIRT1 pathways

doi:10.4330/wjc.v16.i11.632

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 11

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (120)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series.

Item

Count

PDF

HTML

Figures (1-1)

Sum=109

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=2

Nov 26, 2024 (publication date) through Nov 5, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Cardiology

ISSN

1949-8462

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Cardiol. Nov 26, 2024; 16(11): 632-643
Published online Nov 26, 2024. doi: 10.4330/wjc.v16.i11.632

Cardiovascular and nonalcoholic fatty liver disease: Sharing common ground through SIRT1 pathways

Kenneth Maiese

Kenneth Maiese, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20810, United States

Author contributions: Maiese K conceived, designed, and wrote this article.

Supported by American Diabetes Association; American Heart Association; NIH NIEHS; NIH NIA; NIH NINDS; NS053956; and NIH ARRA.

Conflict-of-interest statement: The author reports no conflicts of interest for this article.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Kenneth Maiese, MD, National Heart, Lung, and Blood Institute, National Institutes of Health, Cellular and Molecular Signaling, Bethesda, MD 20810, United States. wntin75@yahoo.com

Received: July 13, 2024
Revised: August 27, 2024
Accepted: October 10, 2024
Published online: November 26, 2024
Processing time: 109 Days and 17.2 Hours

Core Tip

Core Tip: Cardiovascular disease is the principal cause of non-communicable diseases with individuals succumbing to heart disease every thirty-three seconds and has a significant comorbidity with nonalcoholic fatty liver disease (NAFLD). These two disorders impact millions of individuals across the globe, yield significant disability and death to individuals, and have a common underlying cellular pathway with silent mating type information regulation 2 homolog 1 (Saccharomyces cerevisiae) that may offer innovative prospects for the treatment of both cardiovascular disorders and NAFLD.